US FDA launches program to boost domestic drug manufacturing

Source: Reuters

February 1, 2026 12:16 PM EST Updated 4 hours ago


WASHINGTON, Feb 1 (Reuters) - The U.S. Food and Drug Administration on Sunday began accepting requests to participate in its PreCheck pilot program, designed to boost domestic drug supply by speeding up construction and review of drug manufacturing plants in the country.

The FDA said it would select an initial group of new pharmaceutical manufacturing facilities this year based on "alignment with national priorities" in several areas including the product itself, how quickly it can be developed for the U.S. market, and innovations in facility development. "Additional priority considerations will be given to facilities producing critical medications for the U.S. market," the agency said in a statement.

The FDA PreCheck program, first announced in August, aims to streamline review of domestic pharmaceutical plants and eliminate unnecessary regulatory requirements, in line with President Donald Trump's executive order in May to shift manufacturing of drugs to the United States.

The program introduces a two-phase approach to facilitate new U.S. drug manufacturing facilities. The initial phase would provide for more frequent communication with the FDA, including for facility design, construction and pre-production.

Read more: https://www.reuters.com/sustainability/boards-policy-regulation/us-fda-launches-program-boost-domestic-drug-manufacturing-2026-02-01/